Avantor, Inc. (NYSE:AVTR) Shares Sold by Xponance Inc.

Xponance Inc. lowered its position in Avantor, Inc. (NYSE:AVTR) by 2.2% during the 2nd quarter, Holdings Channel.com reports. The firm owned 57,481 shares of the company’s stock after selling 1,293 shares during the quarter. Xponance Inc.’s holdings in Avantor were worth $1,219,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Jennison Associates LLC increased its position in Avantor by 113.0% in the 1st quarter. Jennison Associates LLC now owns 2,497,349 shares of the company’s stock valued at $63,857,000 after acquiring an additional 1,325,026 shares during the period. Swedbank AB acquired a new position in shares of Avantor during the first quarter valued at $2,707,000. Diversify Advisory Services LLC bought a new stake in shares of Avantor during the first quarter valued at about $908,000. CenterBook Partners LP acquired a new stake in Avantor in the fourth quarter worth about $4,562,000. Finally, APG Asset Management US Inc. bought a new position in Avantor in the 4th quarter valued at about $2,971,000. Institutional investors own 95.08% of the company’s stock.

Insider Activity

In other news, CAO Steven W. Eck sold 3,525 shares of Avantor stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $25.06, for a total transaction of $88,336.50. Following the transaction, the chief accounting officer now owns 29,544 shares in the company, valued at $740,372.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.50% of the company’s stock.

Avantor Price Performance

AVTR stock opened at $25.83 on Friday. Avantor, Inc. has a one year low of $16.63 and a one year high of $28.00. The firm has a 50-day moving average of $25.55 and a two-hundred day moving average of $24.39. The firm has a market capitalization of $17.55 billion, a PE ratio of 66.23, a P/E/G ratio of 2.71 and a beta of 1.32. The company has a current ratio of 1.59, a quick ratio of 1.05 and a debt-to-equity ratio of 0.89.

Avantor (NYSE:AVTR) last issued its quarterly earnings results on Friday, July 26th. The company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.23 by $0.02. Avantor had a net margin of 5.28% and a return on equity of 12.40%. The business had revenue of $1.70 billion during the quarter, compared to the consensus estimate of $1.70 billion. On average, analysts forecast that Avantor, Inc. will post 1.01 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have commented on AVTR shares. TD Cowen boosted their price target on shares of Avantor from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Monday, July 29th. Evercore ISI dropped their target price on Avantor from $28.00 to $27.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. Citigroup lowered Avantor from a “buy” rating to a “neutral” rating and decreased their price target for the company from $30.00 to $23.00 in a research note on Wednesday, July 10th. Stifel Nicolaus lifted their price target on Avantor from $27.00 to $28.00 and gave the company a “buy” rating in a research report on Monday, July 29th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $34.00 price objective on shares of Avantor in a report on Thursday. Four equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat, Avantor has an average rating of “Moderate Buy” and a consensus price target of $27.60.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.